On Covaxin approval, Bharat Biotech 'doesn't want to speculate' on WHO's timeline

Indian biotechlogy firm, Bharat Biotech is waiting in anticipation for  World Health Organisation's (WHO) approval of  COVID-19 vaccine Covaxin for Emergency Use Listing (EUL). company informed through a series of tweets on Friday, that COVAXIN clinical trial was entirely compiled and me available by June 2021. Bharat Biotech also tified that necessary data for Emergency Use Listing (EUL) Application was sent to WHO in early July itself. Union Health Minister Mansukh Mandaviya on September 9 h met WHO chief scientist, Dr Soumya Swaminathan and h a productive discussion on WHO's approval of vaccine. 

Bharat biotech doesn't want to speculate on WHO's approval process & timelines

Bharat Biotech maintained that biotechlogy firm h responded to all clarifications on Covaxin vaccine that WHO h sought concerning its approval. y said, "As a responsible manufacturer with past approvals for our or vaccines, we do t find it appropriate to speculate or comment on approval process & its timelines." company while stating this also said that y would continue to work diligently on obtaining WHO EUL as soon as possible.

Covaxin stats: Exhibits high efficiency

Covaxin is a Whole Virion Inactivated Coronavirus Vaccine developed by Bharat Biotech in collaboration with Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV). While phase 3 trials entailed 25,800 participants between 18-98 years of including 10% over of 60, analysis was conducted 14 days after ministering second dose of vaccine. It has shown an overall efficacy of 77.8%, and 93.4% efficacy against severe COVID disease as per final results. On or hand, efficacy data demonstrates 63.6% protection against asymptomatic COVID disease.

Most importantly, it has proven to neutralise variants such as B.1.1.7 (Alpha), B.1.617 (Kappa), B.1.351 (Beta) and B.1.617.2 (Delta). Under aegis of ‘Mission COVID Suraksha - Indian COVID-19 Vaccine Development Mission’, Haffkine Biopharmaceutical Corporation Ltd, Mumbai; Indian Immulogicals Limited in Hyderab and Ankleshwar, and Bharat Immulogicals Biologicals Limited in Bulandshahr have also been permitted to produce Covaxin. 

Im: Twitter/@ANI, PTI